Contineum Therapeutics, Inc. Class A (CTNM) Stock Statistics & Valuation Metrics

Contineum Therapeutics, Inc. Class A has a market cap or net worth of $384.41M. The enterprise value is $276.98M.

Market Cap

$384.41M

Enterprise Value

$276.98M

Contineum Therapeutics, Inc. Class A has 35,353,313 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

35,353,313

Owned by Insiders

0.49%

Owned by Institutions

30.11%

Contineum Therapeutics, Inc. Class A’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -25.28%.

Return on Equity (ROE)

-0.23

Return on Assets (ROA)

-0.22

Return on Invested Capital (ROIC)

-25.28%

Return on Capital Employed (ROCE)

-0.26

Revenue Per Employee

0

Profits Per Employee

-1.18M

Employee Count

51

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Contineum Therapeutics, Inc. Class A is -4.98. Contineum Therapeutics, Inc. Class A’s PEG ratio is -0.21.

PE Ratio

-4.98

PS Ratio

0.00

PB Ratio

1.38

Price to FCF

-5.56

Price to Operating Cash Flow

-6.52

PEG Ratio

-0.21

In the last 12 months, Contineum Therapeutics, Inc. Class A had revenue of 0 and earned -59.98M in profits. Earnings per share was -2.17.

Revenue

0

Gross Profit

0

Operating Income

-68.06M

Pretax Income

-59.98M

Net Income

-59.98M

EBITDA

-67.74M

Earnings Per Share (EPS)

-2.17

In the last 12 months, operating cash flow was -51.87M and capital expenditures -360,000, giving a free cash flow of -52.23M billion.

Operating Cash Flow

-51.87M

Free Cash Flow

-52.23M

Free Cash Flow per Share

-1.36

Contineum Therapeutics, Inc. Class A pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-17.78%

Earnings Yield

-18.54%

Beta

0.27

52-Week Price Change

-15.61%

50-Day Moving Average

12.40

200-Day Moving Average

13.58

Relative Strength Index (RSI)

39.30

Average Volume (3m)

851.10K

Contineum Therapeutics, Inc. Class A upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 03, 2026

Next Earnings Date

Mar 11, 2027

Ex-Dividend Date

―

Contineum Therapeutics, Inc. Class A as a current ratio of 27.50, with Debt / Equity ratio of 3.16%

Current Ratio

27.50

Quick Ratio

27.50

Debt to Market Cap

0.00

Net Debt to EBITDA

0.99

Interest Coverage Ratio

0.00

In the past 12 months, Contineum Therapeutics, Inc. Class A has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Contineum Therapeutics, Inc. Class A EV to EBITDA ratio is -3.12, with an EV/FCF ratio of -4.31.

EV to Sales

0.00

EV to EBITDA

-3.12

EV to Free Cash Flow

-4.31

EV to Operating Cash Flow

-4.34

Contineum Therapeutics, Inc. Class A has $244.48M in cash and marketable securities with $6.27M in debt, giving a net cash position of $238.22M billion.

Cash & Marketable Securities

$244.48M

Total Debt

$6.27M

Net Cash

$238.22M

Net Cash Per Share

$6.74

Tangible Book Value Per Share

$6.39

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Contineum Therapeutics, Inc. Class A is $22.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$22.14

Price Target Upside

151.34% Upside

Analyst Consensus

Strong Buy

Analyst Count

8

Revenue Growth Forecast

―

EPS Growth Forecast

21.55%

Smart Score

5

AI Score

43